You are hereHome > Investor Relations
4:30 PM ET
|OncoGenex First Quarter 2013 Conference Call
Exploring New Compounds to Meet the Challenge of Cancer Treatment Resistance
OncoGenex is a leader in the development of novel therapeutics that target important mechanisms of treatment resistance in cancer. We are committed to the development and commercialization of first-in-class, innovative therapies that have the potential to redefine treatment outcomes for patients with a variety of cancers.
Currently, we have two candidates in clinical development across multiple oncology therapeutic areas and an additional candidate in pre-clinical development:
Custirsen (Phase 3 in prostate and lung cancers)
OncoGenex’s lead compound, custirsen, is an experimental drug designed to block the production of the protein clusterin, which may play a fundamental role in cancer cell survival and treatment resistance. Learn More.
OGX-427 (Phase 2 in bladder, lung, pancreatic and prostate cancers)
OGX-427 is an investigational drug designed to inhibit the production of heat shock protein (Hsp27), a protein that is elevated in many cancers and that has been shown to promote cancer cell growth and tumor metastasis. Learn More.
Stock quote (NASDAQ: OGXI)
Price: 10.66 Change: + 0.49 Volume 63,500
3:21 PM ET on May 23, 2013
Delayed at least 20 minutes. Provided by eSignal.
Webcasts & Presentations
May 2, 2013
4:30 PM ET
|OncoGenex First Quarter 2013 Conference Call||Listen to webcast|
Apr 5, 2013
9:30 AM ET
|Future Leaders in the Biotech Industry Conference||Listen to webcast||View Presentation 1.7 MB|
Mar 7, 2013
4:30 PM ET
|OncoGenex Fourth Quarter 2012 Conference Call||Listen to webcast|
© 2004-2011 OncoGenex Pharmaceuticals Inc. All rights reserved.
OncoGenex product candidates are investigational drugs for use only in approved clinical trials.
OncoGenex Pharmaceuticals is a drug discovery and development company uniquely focused on the challenge of cancer treatment resistance.
OncoGenex is uniquely focused on the challenge of cancer treatment resistance. We currently have several on-going clinical trials that may be of interest to you.
OncoGenex focuses on diverse molecular entities that target mechanisms of resistance and that have the potential to re-define treatment paradigms in a variety of cancers.